Choroidal metastasis: Impact of primary tumors and age on survival - a single center analysis.
Age 59.6 or older independently predicts worse survival in choroidal metastasis.
Choroidal metastasis: Impact of primary tumors and age on survival - a single center analysis.
The purpose of this study was to determine whether patient's age and their primary tumor type act as independent predictors of their survival after a diagnosis of choroidal metastasis.
This retrospective single-center study (August 2013 - August 2025) included 70 patients with choroidal metastases.
Patients aged 59.6+ had about double the death rate, independent of other factors.
Median overall survival was 71.6 weeks.
Statistically significantly longer survival was found in patients <59.6 years (median 88.3 weeks; estimated 3-year survival 33.2%) compared with those ≥59.6 years (median 41.9 weeks; 3-year survival 16.8%; p = 0.037.
Primary tumor group analysis showed a median survival of 94.4 weeks for breast cancer (estimated 3-year survival 38.3%), 52.7 weeks for lung cancer (9,5%), and 40.6 weeks for other primaries (19.7%).
However, this difference was not statistically significant (p = 0.269).
Survival in choroidal metastases is strongly driven by age and the number of extraocular metastatic sites at presentation.
Our findings suggest that younger age and a lower metastatic burden are most reliable indicators for a more favorable prognosis.